Revenue (Tables)

12 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue Within Reportable Segment

The following is a disaggregation of revenue within each reportable segment:

	Fiscal Year
(In thousands)	2023		2022		2021
Medical Device
Product sales	$	34,126	$	27,930	$	21,777
Royalties & license fees – performance coatings		32,812		30,547		31,007
License fees – SurVeil DCB		29,586		5,701		16,049
Research, development and other		9,259		8,211		9,420
Medical Device revenue		105,783		72,389		78,253
In Vitro Diagnostics
Product sales		26,488		26,691		24,701
Research, development and other		313		871		2,182
In Vitro Diagnostics revenue		26,801		27,562		26,883
Total Revenue	$	132,584	$	99,951	$	105,136

Revenue from Customers

Revenue from customers that equaled or exceeded 10% of total revenue was as follows:

	Fiscal Year
	2023			2022			2021
Abbott		27	%		11	%		21	%
Medtronic		10	%		13	%		13	%

Revenue by Geographic Region

Revenue by geographic region was as follows:

	Fiscal Year
	2023			2022			2021
Domestic		82	%		74	%		79	%
Foreign		18	%		26	%		21	%